The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index; 61 of the 111 sources its claims cite were checked for support.
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Open accessPublished version of a preprint
Abstract
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Manufacturing Practice (GMP)–compliant closed and automated systems to ensure reproducibility and to meet the increased demand for patients with cancer. In this review, we describe current CAR T cell clinical manufacturing models and discuss emerging technologic advances that embrace scaling and production optimization. We summarize measures being used to shorten CAR T cell manufacturing times and highlight regulatory challenges to scaling production for clinical use. Significance: As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development. This review provides a critical appraisal of these technologies, which can be leveraged to scale and optimize the production of next-generation CAR T cells. See related video: https://aacrjournals.org/content/webinar-car-t-cell-manufacturing
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes current autologous CAR T-cell manufacturing and emerging closed, automated, and allogeneic platforms intended to scale production. It highlights efforts to shorten manufacturing and QC times while noting regulatory, cost, and variability barriers.
Key findings
- As of April 2021, five commercial CAR T-cell therapies are approved; approved products are second-generation CARs incorporating CD28 or CD137 (4-1BB) co-stimulation, and they achieved complete responses in 32–67% of lymphoma patients, with better CR rates in leukemia.
- By 2026, commercial CAR T-cell therapies are projected to comprise the largest share of oncology drug sales in pediatric and young adult patients with ALL (44%) and adults with DLBCL (46%).
- Rapid manufacturing approaches include the FasT CAR platform, which reduced cell culture time to less than 24 hours; in 10 adolescent and adult patients with CD19+ relapsed/refractory B-ALL, 10/10 (100%) achieved CR on day 15, with only one patient experiencing CRS. Sleeping Beauty–generated CAR T cells shortened ex vivo culture to 14 days, with median CAR expression upon infusion of 86% (range 19%–97%) in six patients.
- Non-viral piggyBac transfection was associated with lymphoma arising from piggyBac-transfected CAR T cells in two of nine patients with relapsed or refractory B-cell malignancies who achieved complete remission; analysis showed increased transgene copy numbers but no integration in typical oncogenes.
Methods
- Narrative review of clinical CAR T-cell manufacturing models, emerging scaling and automation technologies, genetic modification strategies, quality control, and regulatory considerations.
- Synthesizes published literature, clinical trial reports, and regulatory documents; no primary experimental data or systematic search methodology is described.
Limitations
- The paper does not state limitations of the review itself. It extensively discusses field limitations: variability in autologous starting material, open/manual processing, batch-to-batch variation, contamination and human error, viral vector cost and time, expensive closed systems with single-product runs and supply-chain risk, and regulatory discrepancies.
- Evident from the text: as a narrative review, it lacks systematic search criteria, meta-analysis, and primary data; cited trial results and projections come from external sources.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own interpretation · 13 No full text of the sources · 12 Partly supported · 12 Couldn’t confirm · 8 No basis given · 5 Not checked yet · 3 Sources not found · 2 Supported · 2 Supported so far · 1 Not supported · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For a Phase I clinical trial, researchers manufactured an autologous, bispecific CD19/CD22-targeted CAR T cell therapy using the FasT CAR platform, reducing cell culture time to less than 24 hours (117,118).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Could not verifycites [117] Lino, 2018, Delivering CRISPR: a review of the challenges and approaches, Drug Deliv sourceExperimental — accuracy not yet measured
The Introduction discusses earlier gene-therapy trials, and the delivery-method sections discuss CRISPR/Cas9 rather than CAR T-cell manufacturing. Searches for FasT CAR, CD19/CD22, the Phase I trial, and a culture time under 24 hours found no passage addressing the claimed therapy or manufacturing time in our copy. (LLM, conf=0.77)
- Disputedcites [118] Roth, 2018, Reprogramming human T cell function and specificity with non-viral genome targeting, Nature sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes preclinical engineering of NY-ESO-1-targeted TCR cells, not a Phase I trial of bispecific CD19/CD22 CAR T cells. The Methods (Primary human T cell culture, page unavailable) specify two days of stimulation before electroporation, and the Abstract reports ten days of expansion—not cell culture lasting less than 24 hours. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plaindirectn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the composition of autologous starting material from cancer patients is highly variable, influenced by patient age and defects due to underlying disease or pre-treatment with lymphotoxic agents (35-38).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > A decade of advances in CAR T cell manufacture > Quality and quantity of autologous CAR T-cell therapy starting materials.
What the sources say
- Not checked — no full text of the sourcecites [35] Singh, 2016, Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies, Sci Transl Med source
- Partly supportedcites [36] Fesnak, 2020, The challenge of variability in chimeric antigen receptor T cell manufacturing, Regen Eng Transl Med sourceExperimental — accuracy not yet measured
The “Pre-collection source of variability” section identifies underlying disease and prior treatment as drivers of variation in autologous starting material, and describes chemotherapy-associated T-cell depletion and growth defects. It treats age more cautiously, saying it is likely to be a source of variability; the claim presents age as an established influence. (LLM, conf=0.83)
- Partly supportedcites [37] Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability, J Clin Invest sourceExperimental — accuracy not yet measured
The Results describe differences in apheresis starting-material T cells among pediatric patients with relapsed or refractory ALL and compared with healthy donors. The Discussion suggests that recent cytotoxic therapy may contribute to T-cell damage, but does not establish that patient age or underlying disease independently determines starting-material composition. The claim also generalizes this pediatric ALL finding to cancer patients broadly. (LLM, conf=0.85)
- Could not verifycites [38] Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature sourceExperimental — accuracy not yet measured
The Methods section ('Patient samples' and 'CAR T-cell manufacturing and correlative studies'; page not available) describes obtaining autologous T cells but does not assess variability in starting-material composition. Searches for patient age, underlying disease, and prior lymphotoxic treatment found no passage linking those factors to that composition. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Supportedcites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med source
The Case Reports section (page unavailable in our copy) states that peripheral-blood mononuclear cells were collected by apheresis for Patient 1 and used to manufacture CTL019 cells. The Methods section (page unavailable) identifies the trial as one of autologous CTL019 T cells. This paper supports the cited example of a trial using that cell source; it does not independently establish the frequency across all trials. (LLM, conf=0.87)
- Supportedcites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med source
The Materials and Methods sections describe this CAR T-cell trial as using autologous T cells, with peripheral blood mononuclear cells collected from enrolled patients by leukapheresis to manufacture the product. The paper supports the citation as an example of the manufacturing approach; it does not itself establish the proportion of all trials using it. Page numbers were not supplied in the passages. (LLM, conf=0.91)
- Supportedcites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med source
The Case Report states that autologous T cells were collected by leukapheresis, and Results > Cell Infusions states that those cells were transduced to make CAR T cells. This paper supports the cited sentence as an example of a trial using that cell source and collection method; it does not, by itself, establish what most trials used. (LLM, conf=0.90)
- Supportedcites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood source
The Introduction identifies this as a trial using autologous CAR T cells. Results and discussion states that the patient underwent apheresis and that peripheral blood mononuclear cells were used to prepare the cells, confirming this trial as an example of the cited cell-source approach. (LLM, conf=0.90)
- Supportedcites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol source
In “Anti-CD19 CAR T Cells Generated From PBMCs of Heavily Treated Patients” (page not provided), the paper says its CAR T cells were made from autologous PBMCs and describes apheresis for their collection. Among the multiple citations attached to the sentence, this paper supports its role as an example of that manufacturing approach. (LLM, conf=0.90)
- Supportedcites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet source
The Methods (Procedures) state that patients underwent leukapheresis to obtain peripheral blood mononuclear cells and that CAR T-cell manufacturing began on the day of apheresis. The Abstract (Methods) identifies the engineered T cells as autologous. This trial therefore supports the claim as one of the cited examples. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [15] Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients, J Clin Invest source
- Supportedcites [16] Neelapu, 2017, Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma, N Engl J Med source
The Methods (Patients and Study Design; page unavailable) describe leukapheresis followed by axi-cel manufacturing. The introduction (Abstract > Conclusions; page unavailable) identifies axi-cel as an autologous CAR T-cell therapy made from cells removed from the patient. This study supports the cited sentence as an example of that manufacturing approach; it does not itself establish how many trials used it. (LLM, conf=0.88)
- Supportedcites [17] Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med source
The Study Design (p. 2) says all eligible patients underwent leukapheresis and that their cryopreserved material was shipped for manufacturing. This confirms that the cited CAR T-cell trial used patient-derived apheresis material; as one citation among several, it serves as an example rather than evidence for the word “most” on its own. (LLM, conf=0.86)
- Supportedcites [18] Wang, 2020, KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma, N Engl J Med source
The Methods (Patients and Trial Design; page not provided) state that all patients underwent leukapheresis to obtain cells for KTE-X19 manufacturing. As one citation in a list of CAR T-cell trials, this paper supports the sentence by providing an example of patient-derived blood cells collected by apheresis for manufacturing. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Partly supportedcites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med sourceExperimental — accuracy not yet measured
The paper states that the CTL019 receptor includes a CD137 (4-1BB) signaling domain, and the Results report substantial expansion of CTL019 cells in two children. It does not establish that all approved CAR T-cell products are second-generation CARs or that they all incorporate CD28 or CD137; the Methods describe this as a phase 1 trial, not a survey of approved products. No page numbers are available in our copy. (LLM, conf=0.88)
- Partly supportedcites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med sourceExperimental — accuracy not yet measured
The Introduction identifies the study’s CD28-containing CAR as second-generation, and the Discussion describes a second-generation CAR containing 4-1BB. Neither section establishes that all approved CAR T-cell products use one of these designs; the paper discusses clinical studies rather than approved products. Page numbers are not available in our copy. (LLM, conf=0.86)
- Partly supportedcites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies the authors’ CD137 (4-1BB) CAR as second-generation and mentions a separate CD28-linked CAR trial. The paper supports the role of costimulation in expansion and persistence, but it does not assess approved products or establish that all approved CAR T-cell products have either design. (LLM, conf=0.87)
- Partly supportedcites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood sourceExperimental — accuracy not yet measured
The Methods (page not provided) describe this study’s anti-CD19 CAR as containing CD28 and CD3ζ signaling domains, and the Results and discussion report activity in one treated patient. The paper does not establish that all approved CAR T-cell products use CD28 or CD137, or that these signals are essential for effector and memory-cell expansion and persistence. (LLM, conf=0.86)
- Partly supportedcites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol sourceExperimental — accuracy not yet measured
The ‘Anti-CD19 CAR T Cells Generated From PBMCs of Heavily Treated Patients’ section states that the CAR used in this study contained a CD28 costimulatory moiety. The paper does not establish that all approved CAR T-cell products are second-generation CARs or that they use either CD28 or CD137; it describes this study’s construct, not the approved-product class. (LLM, conf=0.87)
- Partly supportedcites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet sourceExperimental — accuracy not yet measured
The Methods describe a trial CAR incorporating a CD28 signalling domain, and the Discussion mentions CD19-CARs incorporating 4-1BB. Neither section establishes that all approved CAR T-cell products are second-generation or use one of those domains; this phase 1 trial is not a survey of approved products. No page numbers are available in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [15] Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients, J Clin Invest source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In 2011, the FDA published a study that acknowledged rapid sterility tests as an alternative (122).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Trends in quality control of the final CAR T cell product
What the sources say
- Could not verifycites [122] Pampusch, 2020, Rapid transduction and expansion of transduced T cells with maintenance of central memory populations, Mol Ther Methods Clin Dev sourceExperimental — accuracy not yet measured
The Materials and Procedure passages describe T-cell transduction and expansion, not sterility-testing policy. Searches for rapid sterility tests and FDA guidance found no passage in our copy addressing a 2011 FDA study or its acceptance of such tests as an alternative. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Murine studies revealed that CAR T cells cultured for only 3 days exhibited superior antitumor activity at a much lower dose (6-fold lower) compared to CAR T cells harvested after a longer culture period (114).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Could not verifycites [114] Abou-El-Enein, 2017, Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment, Cell Stem Cell sourceExperimental — accuracy not yet measured
The passages on CAR T cells (Abstract; page unavailable) discuss clinical genome-editing applications, not murine comparisons of culture duration or antitumor activity. Searches for three-day culture, a six-fold lower dose, and murine antitumor activity found no passage addressing the claim. (LLM, conf=0.73)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Similarly, Knochelmann and colleagues showed in a tumor mouse model that transduced Th17 lymphocytes, a CD4 T cell subset that secretes cytokines such as IL-6, displayed superior antitumor activity after a 4-day expansion than cells expanded for 7 or 14 days (116).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Could not verifycites [116] Wagner, 2019, High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population, Nat Med sourceExperimental — accuracy not yet measured
The SpCas9-specific T cell isolation and expansion section (p. 8) describes human TEFF and TREG cells expanded for 10 days, not transduced Th17 cells in a tumor mouse model. A search for Knochelmann and for the 4-, 7-, and 14-day antitumor comparison found no passage addressing the attributed result. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Furthermore, the manufacturing process must be validated by the end of pivotal clinical trials supporting licensure and release assays (131).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Could not verifycites [131] Sung, 2020, A highly sensitive internally-controlled real-time PCR assay for mycoplasma detection in cell cultures, Biologicals sourceExperimental — accuracy not yet measured
Section 3.1 describes validation of a mycoplasma-detection PCR assay against European Pharmacopoeia performance requirements, not validation of a manufacturing process. Searches for pivotal clinical trials, licensure, and release assays found no passage addressing the claimed validation deadline. The indexed passages provide no page numbers. (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Full implementation of GMP manufacturing rules and regulations in the U.S. is less cumbersome for products manufactured at academic centers for Phase 1 trials (131).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Could not verifycites [131] Sung, 2020, A highly sensitive internally-controlled real-time PCR assay for mycoplasma detection in cell cultures, Biologicals sourceExperimental — accuracy not yet measured
The Abstract describes a mycoplasma-detection PCR assay, and the Discussion addresses its performance as a test for cell cultures. Searches for GMP, Phase 1 trials, and academic-center manufacturing found no passage addressing whether U.S. GMP implementation is less cumbersome in that setting. (LLM, conf=0.77)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In another study, rhesus macaque CAR T cells underwent a 4-day expansion in a G-Rex system after a single rapid transduction step, shortening manufacturing to 9 days (115).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Could not verifycites [115] Wang, 2020, Specificity profiling of CRISPR system reveals greatly enhanced off-target gene editing, Sci Rep sourceExperimental — accuracy not yet measured
The Results section describes CRISPR/Cpf1 specificity assays in HEK293 and HeLa cells, not CAR T-cell manufacturing. Searches for rhesus macaques, G-Rex expansion, rapid transduction, and a 9-day manufacturing schedule found no passage addressing the claim in our copy. (LLM, conf=0.78)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
- It may state two separate claims as one. 36
- Probably not a substantial claim. 20
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although viral vectors have proven efficient in achieving stable gene transfer, their requisite extensive safety testing adds to the cost and time to develop and manufacture CAR T cell products (27,28).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Partly supportedcites [27] Wang, 2015, Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor, J Immunother sourceExperimental — accuracy not yet measured
The Abstract describes successful CAR T-cell engineering with retroviral vectors, and the Results section on vector quality reports an array of release tests, including tests for sterility and replication-competent retrovirus (page not provided). The paper does not say that safety testing itself increases the cost or time of developing and manufacturing CAR T-cell products; its Discussion links cost reduction to improvements in vector production instead. (LLM, conf=0.85)
- Partly supportedcites [28] van der Loo, 2012, Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection, Gene Ther sourceExperimental — accuracy not yet measured
The Results (cGMP production; page unavailable) document extensive safety testing of the manufactured viral vectors. The Introduction also says that certifying stable producer cell banks is lengthy and costly, but it does not establish that safety testing itself adds cost and time to CAR T-cell product development or manufacturing. The paper concerns clinical-grade vector production, not CAR T-cell products. (LLM, conf=0.86)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Further, transduction of cells other than T lymphocytes (e.g. malignant blasts) has been observed, creating the risk of engineering CARs into cancer cells, giving rise to CAR-resistant tumor cells (48).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > A decade of advances in CAR T cell manufacture > Quality and quantity of autologous CAR T-cell therapy starting materials.
What the sources say
- Supportedcites [48] Ruella, 2018, Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell, Nat Med source
The Abstract (page not provided) reports that a leukemic B cell was unintentionally transduced with an anti-CD19 CAR during T-cell manufacturing. Its progeny evaded recognition by CAR T cells and caused resistant leukemia, supporting the stated risk. (LLM, conf=0.94)
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Partly supportedcites [9] Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med sourceExperimental — accuracy not yet measured
The Methods describe this clinical protocol as using a lentiviral vector, and the Abstract says CTL019 was expressed using lentiviral-vector technology. This supports the paper as an example of a clinical protocol using a viral vector, but it does not establish that most protocols or all commercially approved therapies use viral vectors. (LLM, conf=0.88)
- Partly supportedcites [10] Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med sourceExperimental — accuracy not yet measured
Materials and Methods (Generation of 19-28z CAR modified T cells; page unavailable) says the trial's T cells were transduced with gammaretroviral 19-28z supernatant, supporting this protocol as an example of viral-vector delivery. The paper does not establish that most clinical protocols or all commercially approved CAR-T therapies use viral vectors. (LLM, conf=0.88)
- Partly supportedcites [11] Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med sourceExperimental — accuracy not yet measured
The Methods (Study Procedures; page unavailable) describe this clinical trial's use of a lentiviral vector, and the Discussion says the authors used HIV-derived lentiviral vectors. The paper therefore supports an example of a clinical protocol using viral delivery, but it does not establish that most protocols or all commercially approved therapies did so. (LLM, conf=0.88)
- Partly supportedcites [12] Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood sourceExperimental — accuracy not yet measured
The Methods (page not provided) describe a clinical trial that used a retroviral vector to deliver an anti-CD19 CAR into T cells. This supports the paper as an example of a viral-vector clinical protocol, but it does not establish that most protocols or all commercially approved therapies used viral vectors. (LLM, conf=0.88)
- Partly supportedcites [13] Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol sourceExperimental — accuracy not yet measured
The Preparation of Anti-CD19 CAR T Cells and Ex Vivo Assays section (page unavailable) says this clinical study used a gammaretroviral vector encoding the CAR, supporting it as an example of viral-vector delivery. The paper does not establish that most clinical protocols used viral vectors or that all commercially approved therapies did. (LLM, conf=0.86)
- Partly supportedcites [14] Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet sourceExperimental — accuracy not yet measured
The Methods > Procedures section (page not provided) says this clinical trial used a retroviral vector to manufacture CD19-CAR T cells. It does not establish that most clinical protocols or all commercially approved CAR T-cell therapies use viral vectors. (LLM, conf=0.86)
- Partly supportedcites [24] Casati, 2013, Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients, Cancer Immunol Immunother sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes retroviral transduction as a current standard T-cell protocol, and Materials and methods (page unavailable) reports using a retroviral vector. But the vector in this study delivered a TCR, not a CAR; the paper does not establish that most CAR clinical protocols or all commercially approved CAR therapies used viral vectors. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [25] Zufferey, 1997, Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo, Nat Biotechnol source
- Not checked — no full text of the sourcecites [26] Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fully automated closed processes eliminate any handling of the product during manufacturing but are restricted to a single product in each production run (77-79).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > The evolution of CAR T cell manufacturing platforms > Replacing manual processing with automation.
What the sources say
- Partly supportedcites [77] Mock, 2016, Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy, Cytotherapy sourceExperimental — accuracy not yet measured
The Introduction and Discussion (page numbers unavailable) describe automated processing in a closed, single-use tubing set and a single container. But the Discussion says manipulation is minimal, not eliminated, and Table S1 lists hands-on steps during the run. The paper does not establish that the system is restricted to one product per production run. (LLM, conf=0.82)
- Partly supportedcites [78] Jackson, 2020, Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma, Front Immunol sourceExperimental — accuracy not yet measured
The Introduction describes CliniMACS Prodigy as a closed automated CAR-T manufacturing system, and the Discussion reports manufacturing with a GMP-compliant closed system. Neither passage says that the product requires no handling during manufacturing or that a production run is restricted to one product; searches for handling and per-run capacity did not establish those claims. Our copy provides no page numbers for these passages. (LLM, conf=0.83)
- Partly supportedcites [79] Alzubi, 2021, Automated generation of gene-edited CAR T cells at clinical scale, Mol Ther Methods Clin Dev sourceExperimental — accuracy not yet measured
The Introduction and Results describe an automated, closed CAR T-cell manufacturing process. They do not say that it eliminates all product handling or that such processes are restricted to one product per production run; the Results describe product transfer and in-process sampling. (LLM, conf=0.85)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The presence of MDSCs and monocytes can hamper the ex vivo activation and expansion of T cells (40,42-44). Other cellular contaminants such as granulocytes and red blood cells suppress T cell proliferation (45,46).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > A decade of advances in CAR T cell manufacture > Quality and quantity of autologous CAR T-cell therapy starting materials.
What the sources say
- Not checked — no full text of the sourcecites [40] Davis, 2017, Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in non-Hodgkin lymphoma (NHL), Cytotherapy source
- Partly supportedcites [42] Stroncek, 2016, Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells, Cytotherapy sourceExperimental — accuracy not yet measured
The Discussion reports that monocytes and granulocytes in starting PBMC concentrates inhibited CAR T-cell expansion and describes MDSCs as capable of inhibiting T-cell proliferation. It does not establish impaired T-cell activation or suppression by red blood cells. The printed sentence attaches a separate set of citations to the red-blood-cell claim, so this paper most directly supports the expansion portion of the first clause. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [43] Elavia, 2019, Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics, Transfusion source
- Partly supportedcites [44] Noaks, 2021, Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing, Mol Ther Methods Clin Dev sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says monocytes can inhibit T-cell activation and expansion, and the Results report improved activation after monocyte removal in Dynabead-stimulated cultures. The source does not establish the claim about MDSCs. The separate sentence about granulocytes and red blood cells carries different citations, so it is not attributed to this source. (LLM, conf=0.86)
- Supportedcites [45] Long, 2014, T-cell suppression by red blood cells is dependent on intact cells and is a consequence of blood bank processing, Transfusion source
The Results section (‘Intact RBC are required for T cell suppression’) reports that whole packed red blood cells drastically reduced T-cell proliferation. This supports the red-blood-cell portion of the citing sentence; the claims about MDSCs, monocytes, and granulocytes are not attributed to this source. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [46] Munder, 2006, Suppression of T-cell functions by human granulocyte arginase, Blood source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For instance, Panch et al. showed recovery and viability of PBMCs was significantly reduced after freezing and thawing compared to fresh apheresis products (39). Nevertheless, the recovery of mononuclear cells after thawing was sufficient for consistent manufacturing of CAR T cells, without evidence of significant differences in expansion, transduction efficiency or overall subset composition (39)”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > A decade of advances in CAR T cell manufacture > Quality and quantity of autologous CAR T-cell therapy starting materials.
What the sources say
- Partly supportedcites [39] Panch, 2019, Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics, Mol Ther sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Despite clinical success, autologous CAR T cells have sometimes suffered manufacturing delays and, in some instances, had difficulty meeting target doses in commercial production (23).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Could not verifycites [23] Levine, 2017, Global manufacturing of CAR T cell therapy, Mol Ther Methods Clin Dev sourceExperimental — accuracy not yet measured
The sections on scaling manufacturing and ensuring product quality discuss potential challenges, but do not report manufacturing delays or instances in which commercial production failed to meet target CAR T-cell doses. Searches for delays, dose, and target specifications found no passage establishing those events; the target-specifications passage concerns viral vector production instead. (LLM, conf=0.75)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moving toward functionally closed and fully automated manufacturing platforms may enable production scalability and reduce potential human error (71).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > The evolution of CAR T cell manufacturing platforms
What the sources say
- Partly supportedcites [71] Fritsche, 2020, Toward an optimized process for clinical manufacturing of CAR-treg cell therapy, Trends Biotechnol sourceExperimental — accuracy not yet measured
The passage labeled Abstract (page unavailable) describes a move toward nearly closed, (semi)automatic systems and says these reduce costs and batch-to-batch variability. It does not say that such platforms enable production scalability or reduce human error; its separate discussion of scaling up concerns medium supply. (LLM, conf=0.82)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Partly supportedcites [16] Neelapu, 2017, Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Results > Efficacy section reports a 54% complete response rate in 101 patients with refractory large B-cell lymphoma, which falls within the cited 32–67% range. This paper does not establish that range across lymphoma patients or report better complete response rates in patients with leukemia. (LLM, conf=0.88)
- Partly supportedcites [17] Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Efficacy section (p. 4) reports complete responses in 40% of treated adults with diffuse large B-cell lymphoma, including 32% at month 3. The paper does not report a 67% lymphoma complete-response rate. It describes high efficacy in children and young adults with leukemia (p. 2), but does not establish that their complete-response rate was higher. (LLM, conf=0.88)
- Partly supportedcites [18] Wang, 2020, KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Results > Efficacy section reports a 67% complete-response rate among 60 treated patients with relapsed or refractory mantle-cell lymphoma. It does not establish the 32% lower end of the range or compare complete-response rates with those in leukemia patients. Page numbers are not available in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [19] Cohen, 2019, B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma, J Clin Invest source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Currently, five CAR T cell products are approved for commercial use and available on the U.S. market, three for B-cell leukemia and lymphoma (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel), one for mantle cell lymphoma (brexucabtagene autoleucel), and one for multiple myeloma (idecabtagene vicleucel) (2-8).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Partly supportedcites [2] Elsallab, 2020, CAR T cell product performance in haematological malignancies before and after marketing authorisation, Lancet Oncol sourceExperimental — accuracy not yet measured
The Introduction identifies tisagenlecleucel and axicabtagene ciloleucel as approved in the USA for B-cell leukaemia or lymphoma indications. The Conclusion calls them the two approved products discussed in this 2020 paper. Our copy does not support the claim that five products were available on the U.S. market, or the stated approvals for the other three products. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [3] Abramson, 2020, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, Lancet source
- Not checked yetcites [4] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research
- Not checked yetcites [5] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research
- Not checked yetcites [6] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research
- Not checked yetcites [7] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research
- Not checked yetcites [8] U.S. Food and Drug Administration, 2020, Center for Biologics Evaluation and Research
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“On day 15 after cell infusion, 10/10 (100%) patients achieved CR, with only one patient experiencing CRS (118).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Could not verifycites [118] Roth, 2018, Reprogramming human T cell function and specificity with non-viral genome targeting, Nature sourceExperimental — accuracy not yet measured
The Abstract describes NY-ESO-1 TCR-engineered cells reducing tumour burden in treated animals, and Extended Data Figure 10 describes a mouse melanoma model; neither reports outcomes for patients receiving CD19 FasT CAR T cells. Searches for the day-15 10/10 complete-remission result and cytokine release syndrome found no passage addressing those claims. Page numbers were not available in our copy. (LLM, conf=0.76)
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A similar clinical trial phase structure exists in the European Union, although some GMP regulations are stricter in Europe (132,133).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Could not verifycites [132] Cerignoli, 2018, In vitro immunotherapy potency assays using real-time cell analysis, PLoS One sourceExperimental — accuracy not yet measured
The Introduction and Discussion discuss immunotherapy potency assays during development and manufacturing, but neither describes EU clinical trial phases or compares European GMP requirements with those elsewhere. Searches for the EU trial-phase structure and stricter GMP regulations found no passage addressing either claim. (LLM, conf=0.74)
- Could not verifycites [133] Kiesgen, 2021, Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity, Nat Protoc sourceExperimental — accuracy not yet measured
The Introduction section on potency assays describes requirements by clinical-study phase but does not compare EU and US trial structures. Searches for European clinical-trial phases and stricter European GMP regulations found no passage addressing either comparison in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several ranges/measures exist to determine the total T cell number via CD3 expression, to characterize the CD4+ and CD8+ subsets within this population (54), to detect transduced and not transduced cells, and to identify any contaminating cell subsets, such as monocytes/macrophages (CD14) (44).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Trends in quality control of the final CAR T cell product
What the sources say
- Not checked — no full text of the sourcecites [54] Shah, 2020, CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T cell potency and toxicity: updated results from a phase I anti-CD22 CAR T cell trial, J Clin Oncol source
- Supportedcites [44] Noaks, 2021, Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing, Mol Ther Methods Clin Dev source
Table 1 in the Results (page unavailable) identifies CD3 as a pan-T-cell marker, CD4 and CD8 as T-cell subsets, and CD14 as a monocyte marker. The Results also show flow-cytometry gating for transduction efficiency (Figure 3), supporting the distinction between transduced and non-transduced cells. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Disadvantage of these systems include process complexity, need for significant method optimization to overcome low efficiency of CAR expression, need for cell sorting post-engineering (Table S1) and significant cell loss during gene delivery (106).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Adopting non-viral gene delivery systems
What the sources say
- Supportedcites [106] Sherba, 2020, The effects of electroporation buffer composition on cell viability and electro-transfection efficiency, Sci Rep source
The citation is attached to the claim of significant cell loss during gene delivery. The Introduction states that electroporation can cause significant cell death when it is not optimized, and the Results and Discussion (Electroporation outcome score; page unavailable) report low cell viability under some transfection conditions. The paper does not establish cell loss for every non-viral method, but it supports the cited disadvantage for electroporation. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Applying CRISPR/Cas with non-viral delivery of template DNA to eliminate large genes (145) or for orthotopic placement of transgenic constructs (146) could also reduce the potential of off-target effects.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Addressing challenges to genome editing
What the sources say
- Not checked — no full text of the sourcecites [145] Wang, 2019, A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies, Cytotherapy source
- Could not verifycites [146] Harrison, 2017, Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities, Cytotherapy sourceExperimental — accuracy not yet measured
The Introduction defines cell and gene therapies, and the Management of challenging value chains section discusses transfection as a manufacturing step. Neither passage addresses CRISPR/Cas, non-viral template delivery, deletion of large genes, orthotopic placement, or off-target effects; searches for those terms found no relevant passage in our copy. (LLM, conf=0.75)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A U.S. company that seeks to manufacture CAR T-cells in the U.S. and E.U. must comply with both sets of regulations and work with strict oversight from both the FDA and the European Medicines Agency (EMA) to meet respective manufacturing standards (133,135,136).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Partly supportedcites [133] Kiesgen, 2021, Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity, Nat Protoc sourceExperimental — accuracy not yet measured
The Introduction’s “Potency assays for clinical cell therapy products” section describes requirements for potency testing and discusses FDA-approved CAR T-cell products. It does not address EMA oversight or say that a U.S. company manufacturing in both the U.S. and E.U. must comply with both sets of manufacturing regulations. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [135] Digiusto, 2018, Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility, Cytotherapy source
- Not checked — no full text of the sourcecites [136] Abou-El-Enein, 2013, Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs, Cytotherapy source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Decentralized manufacturing in multiple small facilities is appealing, but new models of production scaling that rely on this approach remain a challenge to regulate (137-139).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Not checked — no full text of the sourcecites [137] Abou-El-Enein, 2016, Putting a price tag on novel autologous cellular therapies, Cytotherapy source
- Not checked yetcites [138] U.S. Food and Drug Administration, 2008, Guidance for industry: CGMP for phase 1 investigational drugs
- Could not verifycites [139] Elsallab, 2020, Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: a comparative study with other biologicals, Mol Ther Methods Clin Dev sourceExperimental — accuracy not yet measured
The Discussion describes manufacturing and logistics constraints and regulatory objections for advanced therapies, but does not address decentralized production across multiple small facilities or the appeal and regulatory difficulty of scaling that model. Searches for decentralized manufacturing, scale-out, and multiple facilities found no passage making the attributed point; page numbers were unavailable in our copy. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Most CAR T cells for clinical trials and all commercial CAR T cells use viral vectors for genetic modification (4-8) (Figure 3).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Using viral vectors for genetic modification
What the sources say
- Not checked yetcites [4] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research
- Not checked yetcites [5] U.S. Food and Drug Administration, 2021, Center for Biologics Evaluation and Research
- Not checked yetcites [6] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research
- Not checked yetcites [7] U.S. Food and Drug Administration, 2017, Center for Biologics Evaluation and Research
- Not checked yetcites [8] U.S. Food and Drug Administration, 2020, Center for Biologics Evaluation and Research
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Besides the challenges of obtaining pure and viable starting material, significant batch-to-batch variability exists with autologous cells. Most current manufacturing protocols rely on open, manual processing steps susceptible to operator-introduced errors, contamination, and not easily amenable to scale-out.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > The evolution of CAR T cell manufacturing platforms
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite their advantages in the academic setting, such platforms require trained staff and stringent cleanroom environments, making them less desirable for commercial CAR T cell manufacturing intended for a large number of patients.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, developing allogeneic CAR T cell products may offer an “off-the-shelf” option once certain barriers are overcome.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > The evolution of CAR T cell manufacturing platforms
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“By 2026, commercial CAR T cell therapies are expected to comprise the largest share of oncology drug sales in pediatric and young adult patients with acute lymphocytic leukemia (ALL) (44%) and adults with diffuse large B-cell lymphoma (DLBCL) (46%) (20).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [20] Yip, 2018, The market for chimeric antigen receptor T cell therapies, Nat Rev Drug Discov source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As these therapies reach commercial viability, there has also been a shift in both academia and industry to develop fully closed and automated manufacturing platforms with the potential for scaling.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“While such systems lessen the need for extensive manual handling of the manufactured product, they are expensive to purchase, use costly reagents and disposable culture sets, and may have sole-source providers, which can pose a risk to the supply chain. In addition, each instrument can manufacture only one product at a time, thus, scaling production requires operating parallel instruments.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Introduction
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A single unit of this bioreactor can provide a 500 cm2 gas permeable surface area with 5 L media capacity, which is sufficient to expand large numbers of CAR T cells for clinical applications.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > The evolution of CAR T cell manufacturing platforms > Shifting from open to functionally closed systems.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, automating the manufacturing process may improve process reproducibility and robustness, and potentially lower costs when efficiently employed in large-scale production.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“When manufacturing genetically modified cell-based products, a general problem is the relatively low efficiency of stable gene transfer.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Addressing challenges to genome editing
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“An automated QC testing setup that produces real-time measurements of cell binding and killing allowing for continuous product quality monitoring during the manufacturing process, may prove advantageous (125).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Trends in quality control of the final CAR T cell product
What the sources say
- Not checked — no full text of the sourcecites [125] Yang, 2019, A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed B cell acute lymphoblastic leukemia, Blood source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Especially for CRISPR-Cas technology, there is extensive evidence on potential off-target effects when introducing mutations in undesired genomic loci (142), and induction of host immune responses upon administration (143).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Addressing challenges to genome editing
What the sources say
- Not checked yetcites [142] 2020, CFR - Code of Federal Regulations Title 21 - Food and Drugs
- Not checked — no full text of the sourcecites [143] Gaspar Ernesto, 2020, Pharmaceutical manufacturing in the EU and the EU–US mutual recognition agreement, PDA J Pharm Sci Technol source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Since the traditional scale up model of drug manufacturing can at least be partially applied to allogeneic CAR T cell manufacturing, it may offer a theoretical scaling advantage over the autologous model.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“T cells engineered using Sleeping Beauty were infused less than two days post-electroporation, suggesting that the engineered T cells were infused without full characterization (NCT03579888).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Not matchedcites NCT03579888
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“Full GMP compliance is required for Phase I clinical trials which could be cumbersome for academic developments (134).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Not checked — no full text of the sourcecites [134] Abou-El-Enein, 2017, Strategies for derisking translational processes for biomedical technologies, Trends Biotechnol source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Broadly accepted levels of standardization for CAR T cell manufacturing will enable a more rapid assessment by regulatory authorities and facilitate technology transfer.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If the benefit-risk assessment is favorable, separate biologics licenses could be issued to individual sites to allow independent manufacturing at each site.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such an advancement, if accepted by regulatory agencies, would significantly accelerate product release and improve overall scalability.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Trends in quality control of the final CAR T cell product
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Recent efforts have focused on reducing the duration of the CAR T cell expansion step which, in turn, reduces vein-to-vein manufacturing time.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.
In the paper
“Researchers at M.D. Anderson Cancer Center in collaboration with Ziopharm reported that six patients with active CD19+ lymphoid malignancy were infused with CAR T cells manufactured using this system. Median CAR expression upon infusion was 86% (range 19%-97%), resulting in anti-tumor effects and no clinically significant CRS.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Efforts to shorten CAR T cell manufacturing time
What the sources say
- Not checked — no full text of the sourcecites [119] Schober, 2019, Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function, Nat Biomed Eng source
plaindirectn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the approaches discussed here are mutually exclusive with the current model of autologous CAR T cell manufacturing.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moreover, besides the need for biodistribution studies and integration-site analysis, regulatory expectations also include establishing reliable off-target screening strategies with a robust validation of pre-determined target sites to evaluate the extent of nuclease-induced off-target mutagenesis.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Addressing challenges to genome editing
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In such model, automated platforms could simplify the workflow, increase process robustness, enable scalability, and reduce costs, while maintaining or even improving the efficacy of the resulting CAR T cell products.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As discussed earlier, considerable variability can hinder CAR T cell manufacturing.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Recently, the FDA discussed decentralized manufacturing (140), which entails product manufacturing according to the same protocol at different sites and analyzing pooled safety and efficacy data.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Not checked yetcites [140] European Medicines Agency (EMA), 2017, Guidelines on good manufacturing practice specific to advanced therapy medicinal products
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The emergence of new tools such as the fusion between reverse transcriptase and catalytically impaired Cas9 endonuclease might enable the delivery of gene cassettes without the need for double-strand breaks (DSB) which also induces much lower off-target editing (147).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Genetic modification strategies for CAR T cells > Addressing challenges to genome editing
What the sources say
- Not checked — no full text of the sourcecites [147] Marks, 2018, Balancing safety and innovation for cell-based regenerative medicine, N Engl J Med source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although this may require additional time for up-front validation, reduction in costs and in lead time delays could eventually be realized through efficiency of logistics and the overall production process.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Products developed in smaller academic centers equipped with GMP laboratories could be used to treat patients at regional medical centers.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Allogeneic products, however, may become the model of choice for products manufactured at scale in larger centralized commercial facilities, once the limitations discussed above can be overcome.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Conclusion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
In the paper
“qPCR assays for the detection of mycoplasma are now standard and reduce assay time from 28 days to 1-2 days (124).”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Trends in quality control of the final CAR T cell product
What the sources say
- Not checked — no full text of the sourcecites [124] Zhang, 2019, CD19-directed fast CART therapy for relapsed/refractory acute lymphoblastic leukemia: from bench to bedside, Blood source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The FDA has noted that one of the major issues in the implementation of this model is having a sufficient understanding of the critical quality attributes of the product, so that the consistency of its manufacture can be assured from site to site.”
§ Scalable Manufacturing of CAR T cells for Cancer Immunotherapy > Other considerations for scaling CAR T cell production
What the sources say
- Not checked yetcites [140] European Medicines Agency (EMA), 2017, Guidelines on good manufacturing practice specific to advanced therapy medicinal products
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The demand for CAR T cell therapies will continue to increase, including for solid tumors, making scalable manufacturing necessary.
“As demand for CAR T cell therapies increases, particularly when therapies for solid tumors have reached commercial stages, developing manufacturing platforms that enable scaling while embracing the principles of “quality by design,” will be crucial.”
The paper relies on this without support.
Cells from healthy donors have not been exposed to chemotherapies and are free of tumor cells.
“Since cells from healthy donors have not been exposed to chemotherapies and are free of tumor cells, their quality is expected to be superior to those obtained from cancer patients.”
The paper relies on this without support.
Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.
“Shortening CAR T cell manufacturing time will enable patients with aggressive disease to receive treatment sooner.”
The paper relies on this without support.
Among QC parameters, sterility tests require the most time.
“Of these parameters, the sterility tests require the most time.”
The paper relies on this without support.
Currently, compendial product sterility tests take 14 days, and the fungal assay can take up to 42 days.
“Currently, the compendial product sterility tests take 14 days, and the fungal assay can take up to 42 days.”
The paper relies on this without support.
Anaerobic and aerobic enriched media testing that takes 7 days is recognized by the European Pharmacopeia as an alternative rapid test.
“Anaerobic and aerobic enriched media testing that takes 7 days is recognized by the European Pharmacopeia as an alternative “rapid” test.”
The paper relies on this without support.
The FDA does not formally recognize rapid tests.
“However, the FDA does not formally recognize rapid tests.”
The paper relies on this without support.
Most manufacturers characterize the final CAR T-cell product by flow cytometry, with many characterization panels currently in use.
“Most manufacturers characterize the final CAR T-cell product by flow cytometry, with many characterization panels currently in use.”
The paper relies on this without support.
Qualification and validation of the assay are required prior to obtaining a BLA, which is needed in the U.S. for commercial manufacturing.
“Qualification and validation of the assay are required prior to obtaining a BLA, which is needed in the U.S for commercial manufacturing.”
The paper relies on this without support.
Currently, each manufacturer specifies their own potency assay and develops specific parameters in agreement with regulatory agencies for their clinical grade product.
“Currently, each manufacturer specifies their own potency assay and develops, in agreement with the regulatory agencies, specific parameters appropriate for the clinical grade product they manufacture.”
The paper relies on this without support.
To date, there is no consensus on a potency assay or platform that can accurately predict clinical response to CAR T cell therapy.
“To date, there is no consensus on a potency assay or platform that can accurately predict clinical response to CAR T cell therapy.”
The paper relies on this without support.
Variable gene expression is unavoidable in current CAR T cell generation protocols owing to retro- and lentiviral vector integration.
“While variable gene expression is unavoidable in current CAR T cell generation protocols owing to retro- and lentiviral vectors integration, variabilities in other manufacturing parameters can be better controlled by adopting “Quality by Design” (QBD) principles (Figure 4).”
The paper relies on this without support.
Clinical-grade reagents add to overall costs but are necessary to ensure quality of administered CAR T cell products.
“These reagents add to the overall costs but are necessary to ensure the quality of the administered CAR T cell products.”
The paper relies on this without support.
Properly trained production and QC staff under GMP conditions is a key element in product manufacture.
“Production and QC staff properly trained to work under GMP conditions is another key element in product manufacture.”
The paper relies on this without support.
CIRM recognizes the need for training a GMP workforce and offers educational grants to train students on cell therapy manufacturing.
“This need has also been recognized by the California Institute for Regenerative Medicine (CIRM), which offers educational grants to train students on cell therapy manufacturing.”
The paper relies on this without support.
In the United States, the FDA requires demonstration of safety and substantial evidence of efficacy from clinical trials, and data from these trials are used to apply for a BLA.
“In the United States, the FDA requires the demonstration of safety and substantial evidence of efficacy from clinical trials. Data from these trials are then used to apply for a Biologics License Application (BLA).”
The paper relies on this without support.
For Phase 2 or 3 clinical trials, the FDA more tightly regulates the process.
“For Phase 2 or 3 clinical trials, however, the FDA more tightly regulates the process.”
The paper relies on this without support.
Gene-modified cellular products are subjected to greater regulatory scrutiny in the E.U. than non-gene modified therapies.
“Also, gene-modified cellular products are subjected to greater regulatory scrutiny in the E.U. than non-gene modified therapies.”
The paper relies on this without support.
Developers have been keen on setting up production facilities in the respective geographical areas to fully comply with the local regulatory landscape.
“Therefore, developers have been keen on setting up production facilities in the respective geographical areas to fully comply with the local regulatory landscape.”
The paper relies on this without support.
To increase accessibility of autologous CAR T cell products, some therapies in development are transitioning toward decentralized manufacturing.
“To increase the accessibility of autologous CAR T cell products, some therapies in development are transitioning toward decentralized manufacturing.”
The paper relies on this without support.
Novel approaches to shorten the manufacturing process are being developed, such as non-viral vector approaches relying on electroporation of primary cells.
“Finally, novel approaches to shorten the manufacturing process are being developed, such as non-viral vector approaches relying on electroporation of primary cells.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A paradigm shift enabling POC manufacturing is the development of bioreactors and closed system manufacturing platforms that mitigate the need for expensive infrastructure and simplify the multistep process.2,8,9”
From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationAbramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Cited by
Sorted by citations
Items 301–322 of 322
Nuijten, M., & van Gelder, P. H. A. J. M. (2026) · Journal of Market Access & Health Policy · doi:10.3390/jmahp14030047
Lee, E. H., Safford, M., Staab, T., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102978
CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting
Zhang, M., Zhao, L., Chen, T., Ding, L., He, L., & Guo, Z. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117231
Atsumi, Y., Niwa, A., Kitagawa, Y., Kumaki, T., Yagyu, S., Nakazawa, Y., & Saito, M. K. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102976
Harnessing the Power of CAR-T Cells in Hematologic and Solid Tumors
Habibi, S., Jalise, S. Z., Afkhami, H., et al. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_7
He, F., Zhu, X., Wang, X., Ju, X., Wu, F., Di, W., Su, S., & Huang, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108368
Shi, M., Liu, Y., Chen, H., Wang, Y., Zhao, L., Wang, X., Li, X., Liu, M., Wang, J., Wang, T., et al. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70332
Zelluläre Therapien in der Lungenmedizin: Neue Perspektiven bei Infektionskrankheiten und Tumoren
Jantz-Naeem, N., Hasdorf, J., Proemmel, M., Mougiakakos, D., Kahlfuss, S., & Fricke, S. (2026) · Deutsches Ärzteblatt Online · doi:10.3238/perspneumo.2026.08.21.02
Zhu, Y., Yu, J., Kim, Y. J., Tian, Y., Li, Z., Chen, Y., Lyu, Z., Zhu, E., Zhao, A., Ma, N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102998
Cabrera-Salcedo, S. C., Parra‐Lara, L. G., Fernandes-Pineda, M., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Ortiz‐Guzman, J., García-Robledo, J. E., Cañas, C. A., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1875553
Nezhad, M. S. H., Gol, S. Z., Gharavi, P., & Javid, H. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12720-y
Shin, H. S., & Choi, S. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7442995
Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
Zayed, O., Ibrahim, L., & Mansour, A. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/4fcjcte0z4
Otegbeye, F., Hanley, P. J., Hopewell, E. L., Grilley, B., Sturtevant, O. J., Kurtzberg, J., & Tressler, R. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103027 · Cited by 1
Sun, M., Dengju, L. I., & Wei, J. (2026) · MedComm · doi:10.1002/mco2.71029
Fuentes-Bustos, H. E., Hernández-López, A., Zapata‐Tarrés, M., Bustamante‐Ogando, J. C., Segura-Pacheco, B. A., Olaya-Vargas, A., & Meneses‐Acosta, A. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1917849
Shaz, B. H., Gupta, D., Dinh, A., Schwartz, J., Thibodeau, S., & Fontaine, M. J. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103034
Irwin, S. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch013
Wu, Q., Jiang, M., Li, Y., Huo, H., Cheng, H., Jia, T., Wang, Y., Wang, Z., Ji, M., Lin, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1981337
Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
Bai, Y.-S., Qin, J.-T., Dai, Z.-J., Yan, R., Yang, Y., & Wang, W.-G. (2026) · Exploration · doi:10.1002/exp2.70230
Sotomayor, P., Prochazka, L., & Brockhaus, M. (2022) · Pharma Research · doi:10.62655/s-epub.2022.v14.i01.pp53-62
Metadata
- Authors
- Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B.
- Affiliations
- 1Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
- University of Southern California (US)
- Stanford Cancer Institute (US)
- University of Pennsylvania (US)
- Houston Methodist (US)
- Center for Biologics Evaluation and Research (US)
- Fred Hutch Cancer Center (US)
- University of California, Davis (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Blood Cancer Discovery
- Published
- 2021-08-03
- Volume
- 2
- Issue
- 5
- Pages
- 408-422
- ISSN
- 2643-3230 (ISSN-L)
- 2643-3249
- PMC
- PMC8462122
- OpenAlex
- W3190521604
- Semantic Scholar
- 292a0bb64b8809ead2a11f9da2048d96231f0620
- Cited by
- 321
- References
- 143
- Citations by year
- 2026: 79 · 2025: 81 · 2024: 81 · 2023: 37 · 2022: 41 · 2021: 2
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood Cancer Discovery (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NCI (P50CA126752)
- American Association for Cancer Research (SU2C-AACR-DT-29–19)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- chimeric antigen receptor T cells, chimeric antigen receptor, T cell manufacturing, scalable fabrication, good manufacturing practices, hematologic malignancies, production time reduction, regulatory challenges, production optimization
- MeSH terms
- Humans, Neoplasms, T-Lymphocytes, Reproducibility of Results, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
